Einer Elhauge
Article Abstract:
Einer Elhauge, Professor of Law at Harvard Law School and the faculty director of new center, born to Argentinean parents, was an undergraduate in biochemical sciences and spent one year in medical school before taking a leave of absence to go to law school. Elhauge believes that leading law schools does not have much of a presence in health law and feels that biotechnology is one of the main cause of current health law issues.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Genentech discloses safety concerns over Avastin
Article Abstract:
Genentech and the US Food and Drug Administration (FDA) sent a notice to physicians regarding the Genentech's antibody drug, Avastin. The notice warns other companies that similar drugs targeting the endothelium may raise safety concerns when used in combination therapy.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Cancer Pathways' target not validated by clinical results
Article Abstract:
Share prices of Cell Pathways dropped after reports that the Phase III clinical trial conducted on Exisulind did not achieve the expected results when compared to a placebo response.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Serum proteomics profiling- a young technology begins to mature
- Abstracts: Oshkosh demonstrates new robotic truck. Officers: slat armor does not contribute to Stryker rollovers
- Abstracts: Shaping hedges. Charity changes. Global times
- Abstracts: 'Green' PR rises to meet challenges posed by new activist Congress. Little green 'buzz' reflects environmental progress
- Abstracts: Dual selection enhances the signaling specificity of a variant of the quorum-sensing transcriptional activator LuxR